Item 1.01 - Entry into a Material Agreement

On August 6, 2008, PhytoMedical Technologies, Inc. entered into a exclusive worldwide license agreement (the "License Agreement") with Dartmouth College to develop, market and distribute new anti-tumor bis-acridines, bis-ellipticines and bis-carbazoles known as intercalating agents developed by leading researcher, Dr. Gordon Gribble, of Dartmouth College.

A redacted copy of the exclusive worldwide License Agreement is attached to this Current Report on Form 8-K dated October 21, 2008 as Exhibit 10.1 and incorporated herein by reference.

CONFIDENTIAL PORTIONS OF THE LICENSE AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER A CONFIDENTIAL TREATMENT REQUEST OF EVEN DATE HEREWITH, PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED, AND RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [****].

A copy of the press release announcing our entry into the License Agreement with Dartmouth College was attached to the Current Report on Form 8-K dated August 6, 2008 as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

The following exhibits are furnished as part of this report:

Exhibit 10.1 - Redacted version of the Exclusive Worldwide License Agreement entered into August 6, 2008 between PhytoMedical Technologies, Inc. and the Trustees of Dartmouth College. CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER A CONFIDENTIAL TREATMENT REQUEST, PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED, AND RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [****].

---